The primary aim of the investigation was to determine whether eccentric exercise would augment the release of the myokine fibroblast growth factor 21 (FGF21) and/or its regulatory enzyme, fibroblast activation protein (FAP), from skeletal muscle tissue into the systemic circulation of healthy human volunteers. Physically active young healthy male volunteers (age 25.0 ± 10.7 years; body mass index 23.1 ± 7.9 kg m −2 ) completed three sets of 25 repetitions (with 5 min rest in between) of single-leg maximal eccentric contractions using their non-dominant leg, whilst the dominant leg served as a control. Arterialized blood samples from a hand vein and deep venous blood samples from the common femoral vein of the exercised leg, along with blood flow of the superficial femoral artery using Doppler ultrasound, were obtained before and after each exercise bout and every 20 min during the 3 h recovery period. Muscle biopsy samples were taken at baseline, immediately and 3 and 48 h postexercise. The main findings showed that there was no significant increase in total or bioactive FGF21 secreted from skeletal muscle into the systemic circulation in response to exercise. Furthermore, skeletal muscle FGF21 protein content was unchanged in response to exercise. However, there was a significant increase in arterialized and venous FAP concentrations, with no apparent contribution to its release from the exercised leg. These findings raise the possibility that the elevated levels of FAP might play a role in the inactivation of FGF21 during exercise.
INTRODUCTION
The endocrine ability of skeletal muscle to secrete particular proteins (referred to as myokines) into the systemic circulation to facilitate cross-talk with other tissues is well established (Raschke, Eckardt, Bjørklund Holven, Jensen, & Eckel, 2013) . In particular, myokines secreted in response to exercise have a variety of positive effects on chronic diseases and metabolic disorders (Pedersen & Febbraio, 2008) .
Fibroblast growth factor 21 (FGF21) has been identified as a novel myokine (Izumiya et al., 2008) and is a key regulator of energy metabolism and plasma glucose homeostasis (Kharitonenkov et al., 2005) . The major site of FGF21 production is the liver, but it can also be synthesized in adipose tissue, pancreas and skeletal muscle in c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society response to specific stimuli and functions in a paracrine and/or endocrine fashion in these tissues (Tacer et al., 2010) . Recently, FGF21 has been suggested to act as an exercise-induced myokine , and muscular contractions have been identified as key stimuli in inducing hepatic release of FGF21 in humans. Indeed, studies have shown FGF21 serum concentrations to be elevated after endurance exercise between 50 and 80% of maximal oxygen consumption (Cuevas-Ramos et al., 2012; Tanimura et al., 2016) . However, in those conditions most of the release of FGF21 into the systemic circulation occurred from the liver rather than skeletal muscle (Hansen et al., 2015) . Collectively, the results from the literature suggest that FGF21 might be a stress-induced hormone rather than an exercise-induced myokine.
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New Findings
• What is the central question of this study?
The role of FGF21 as an exercise-induced myokine remains controversial. The aim of this study was to determine whether eccentric exercise would augment the release of FGF21 and/or its regulatory enzyme, fibroblast activation protein (FAP), from skeletal muscle tissue into the systemic circulation of healthy human volunteers.
• What is the main finding and its importance?
Eccentric exercise does not release total or bioactive FGF21 from human skeletal muscle. However, exercise releases its regulatory enzyme, FAP, from tissue(s) other than muscle, which might play a role in the inactivation of FGF21.
Interestingly, most studies have used protocols consisting of exercise involving concentric contractions. Despite the growing interest in the metabolic benefits of eccentric training on young and elderly populations (LaStayo, Reich, Urquhart, Hoppeler, & Lindstedt, 1999; Perrey, Betik, Candau, Rouillon, & Hughson, 2001; Vallejo, Schroeder, Zheng, Jensky, & Sattler, 2006) , there is a paucity of studies investigating the effects of eccentric exercise on myokine release in humans. Moreover, it should be noted that all studies to date involving FGF21 have measured only the total amount of FGF21 in circulation.
Although the biological actions of FGF21 depend on intact amino acid sequences in its N and C termini (Micanovic et al., 2009) , its activity and stability in the circulation and the mechanisms regulating these processes in humans remain largely unknown. Recently, fibroblast activation protein (FAP) was described as a serine protease that cleaves and inactivates FGF21 (Zhen, Jin, Ackermann, Thomas, & Gutierrez, 2016) . Interestingly, patients with type 2 diabetes have elevated circulating levels of FAP, and this is associated with an attenuated ratio of bioactive to total FGF21 in response to an oral glucose tolerance test (Samms et al., 2017) . However, the effects of exercise in these processes have not been investigated.
The aim of this study was to evaluate, for the first time, the effects of exercise on both the bioactive (intact) and total forms of circulating FGF21 along with the levels of FAP, and to test the hypothesis that performing maximal eccentric muscle contractions will augment the release of FGF21, along with other well-established myokines, such as interleukin 6 (IL6), from muscle tissue into the systemic circulation owing to greater muscle structural disruption and increased inflammatory responses normally associated with eccentric exercise.
METHODS

Ethical approval
The study was approved by the University of Nottingham Faculty of
Medicine and Health Sciences Research Ethics Committee (reference no. I08122015 SoLS) and complied with the present guidelines set out in the Declaration of Helsinki, except for registration in a database.
Before any participation, all subjects were fully briefed on all aspects of the study and thereafter signed a written informed consent.
Subjects and preliminary tests
Eight young healthy men (age 25.0 ± 10.7 years, height 177.5 ± 20.4 cm, body mass 73.3 ± 33.4 kg, body mass index 23.1 ± 7.9 kg m −2 ) participated in the study. All subjects were physically active individuals but unaccustomed to maximal eccentric exercise. All subjects took part in an individual medical screening that consisted of completing health and physical activity questionnaires, having a 12-lead ECG and blood pressure measured and a blood sample taken for routine screening. All eligible subjects were then asked to complete a 3 day food diary (two weekdays and one weekend) in order to assess their habitual dietary intake that allowed the design of the 2 day isoenergetic standardized diet (50% energy from carbohydrate, 30%
from fat and 20% from protein) that was required to be adhered to over the course of the experiment.
All subjects attended a preliminary laboratory session to familiarize themselves with the exercise testing procedure. This session consisted of a 10 min warm-up period using submaximal cycling and stretching, 
Experimental protocol
After the familiarization visit, all subjects attended the laboratory on two more occasions separated by 48 h (main experimental visits; a schematic diagram of the experimental protocol is shown in Figure 1 ).
On the first occasion, subjects arrived at the laboratory at ∼08.00 h after an overnight fast (10-12 h), having abstained from heavy exercise and alcohol and having consumed the standardized mixed diet (described in section 2.2) for the previous 24 h. Subjects were then asked to rest on a bed in a semi-supine position, and an I.V. cannula was inserted retrograde into the superficial hand vein of one arm for arterialized venous blood sampling for the determination of bioactive and total FGF21, FAP and IL6 concentrations. The hand thereafter remained in a hand-warming unit (50-55 • C) with the hand and air temperature continuously monitored (Gallen & Macdonald, 1990 Net flux of M (pg min −1 or mg min −1 ) = Blood flow
Baseline muscle biopsy samples were obtained from the vastus lateralis of both legs (control and exercised) using the needle biopsy technique for the determination of intramuscular protein levels of FGF21 using Western blotting. Muscle biopsy samples were also taken immediately postexercise and after the 3 h recovery period from the exercise leg only, during which subjects were rested on a bed in a semisupine position.
After completion of all baseline measurements, subjects under- Subjects then rested on a bed in a semi-supine position for 3 h.
Thereafter, they were provided with a standardized carbohydraterich lunch (consisting of pasta, tomato sauce and cheddar cheese) and asked to consume a standardized isoenergetic mixed diet providing 50% energy from carbohydrate, 30% from fat and 20% from protein for the next 48 h. All subjects were subsequently allowed to leave the laboratory.
Forty-eight hours after the end of the last bout of maximal eccentric muscle contractions, subjects returned to the laboratory after an overnight fast, having abstained from heavy exercise and alcohol in the intervening period. Upon arrival in the laboratory, subjects were asked to rest on a bed in a semi-supine position, and a single arterialized blood sample was obtained from a superficial hand vein. After this, a muscle biopsy sample was obtained from the vastus lateralis of both legs (control and exercised). In total, six muscle biopsy samples were obtained: at baseline, immediately postexercise and after 3 and 48 h of recovery from exercise in the exercised leg, and at baseline and 48 h postexercise in the control leg. Subjects subsequently performed the same muscle function tests conducted during the previous visit, using the previously exercised leg to assess the extent to which muscle function had been restored after the performance of the eccentric protocol 48 h beforehand. After the completion of that visit, subjects were provided with lunch and then allowed to leave the laboratory.
Blood analysis
Blood samples were centrifuged immediately after collection at 10,000g for 10 min at 4 • C to obtain plasma. Bioactive FGF21, the 
Skeletal muscle biopsy and analysis
All muscle samples were obtained from the vastus lateralis using the needle biopsy technique, with suction being applied. Each sample from each leg was taken through a separate skin incision (3-5 mm long)
at least 2 cm apart. All incisions were made using a surgical blade under local anaesthetic (2-3 ml of 1% lidocaine). Upon collection, muscle samples were rapidly frozen in liquid nitrogen-cooled isopentane before being stored in liquid nitrogen for subsequent analysis. 
Statistical analysis
Data analysis was carried out using GraphPad Prism 7 Software (GraphPad Software Inc., San Diego, CA, USA). Isometric and isokinetic measurements, including fatigue index, were analysed using Student's paired t test with Bonferroni corrections. Blood hormones and enzymes, blood flow, Western blot data and eccentric peak torque measurements were analysed using one-way repeatedmeasures ANOVA using Bonferroni corrections. Data are reported as means ± SD, and statistical significance was set at P < 0.05.
RESULTS
Exercise tests
There was no difference in maximal isometric strength between baseline (21 ± 5 kg) and 48 h after exercise (21 ± 8 kg). Maximal isokinetic concentric peak torque also showed no significant difference between baseline (166 ± 49 N m) and 48 h postexercise (149 ± 66 N m).
Furthermore, there was no difference in isokinetic concentric total work output between baseline (1489 ± 448 N m) and 48 h postexercise (1326 ± 585 N m). There was no significant difference in the amount of fatigue experienced when conducting maximal isokinetic concentric contractions during baseline and 48 h postexercise.
Maximal eccentric peak torque showed no significant difference between set 1 (147 ± 54 N m), set 2 (128 ± 59 N m) and set 3 (140 ± 65 N m). However, maximal eccentric total work output showed a significant decrease over time (P < 0.01) between set 1 (4371 ± 1848 N m) and set 3 (3536 ± 1298 N m).
Total plasma FGF21
Total FGF21 in arterialized blood showed no significant differences between baseline and all subsequent time points (Figure 2a) . Likewise, there was no change in total FGF21 in the deep venous blood of the exercised leg in response to exercise and subsequent 3 h recovery ( Figure 2b) . As a consequence, there was no difference over time in the arteriovenous differences of total FGF21 and its flux across the exercised upper leg (Figure 2c ).
Bioactive plasma FGF21
There were no changes in the concentrations of the bioactive form of FGF21 in arterialized blood ( Figure 2d ) and deep venous blood of the exercised leg (Figure 2e ) from baseline to all exercise and postexercise time points. Thus, there were no significant changes over time in arteriovenous differences of bioactive FGF21 and its flux across the exercised upper leg (Figure 2f ). The ratio of bioactive to total FGF21 was 0.65 ± 0.59 at baseline and was unaffected by exercise (maintained at 0.91 ± 0.59 throughout the 3 h recovery period).
Plasma FAP
There was an increase (P < 0.05) in arterialized FAP levels during the exercise period (Figure 2g ). Likewise, deep venous FAP in the exercised leg also showed a significant increase during the exercise period (P < 0.05; Figure 2h ). Both concentrations returned to basal 
Plasma IL6 concentrations
Arterialized plasma IL6 concentrations showed a significant increase (P < 0.0001) in response to the 3 h recovery from exercise (Figure 3a) .
In contrast, deep venous IL6 concentrations in the exercised leg showed an earlier increase in response to the second and third bout of exercise (P < 0.05) and the subsequent 3 h recovery period (P < 0.0001; Figure 3b ). However, there was a greater increase in deep venous IL6 concentrations compared with the arterialized levels, resulting in negative (P < 0.001) arteriovenous differences between 40 and 160 min of the recovery period, indicating a net release (P < 0.01) of IL6 from the working muscle throughout that period (Figure 3c ).
Muscle FGF21 protein content
There were no significant differences in muscle FGF21 protein content in the exercised leg between baseline and all subsequent postexercise time points (Figure 4 ). There were also no significant differences in FGF21 muscle protein content in the control leg between baseline and 48 h postexercise (Figure 4) . Effect of exercise on plasma IL6 concentrations at baseline (BL), immediately before exercise (P-Ex), during exercise (sets 1, 2 and 3; S1-S3) and subsequent recovery (0-180 min). (a-c) Plasma IL6 (in picograms per millilitre) in arterialized blood, n = 8 (a), in deep venous blood of the exercised leg, n = 6 (b) and net flux across (release from) the exercised leg (in picograms per minute), n = 6 (c). Values represent means ± SD. * P < 0.05, ** P < 0.01; *** P < 0.0001 from baseline. The shaded grey area represents the exercise period (sets 1, 2 and 3)
DISCUSSION
The present study demonstrated that maximal eccentric contractions do not cause the release of total or bioactive FGF21 from human skeletal muscle tissue into the systemic circulation. This suggests that, in the conditions of the present study, FGF21 may not be considered an exercise-induced myokine. This was supported by the observation that (Pedersen & Febbraio, 2008) .
The finding from the present study that FGF21 is not released from skeletal muscle in response to maximal eccentric exercise supports the data acquired by Hansen et al. (2015) demonstrating no release of FGF21 from the exercising leg in response to submaximal concentric exercise in humans. Likewise, data presented by from a study conducted on mice showed that exercise increased hepatic but not skeletal muscle Fgf21 mRNA. Collectively, the data from the present and the aforementioned studies indicate that in response to both submaximal and maximal contractions, FGF21 is not released from skeletal muscle. Moreoever, the studies by Hansen et al. (2015) and indicate that the liver is the main source of FGF21 secretion into the systemic circulation in resting and exercised conditions in humans. It should be noted that in the present study FGF21 protein content in skeletal muscle was measured for up to 48 h postexercise, unlike the studies by Hansen et al. (2015) and , in which only mRNA was measured. Although exercise did not cause the induction of FGF21 protein in skeletal muscle, the possibility of FGF21 as a non-exercise myokine exerting localized autocrine or paracrine effects cannot be totally discarded. Indeed, mitochondrial dysfunction induced by autophagy deficiency in skeletal muscle tissue results in the secretion of FGF21 (Kim, Jeong et al., 2013) . Subsequently, mitochondrial dysfunction induced in transgenic mice resulted in significant increases in plasma FGF21 and its mRNA levels in skeletal muscle (Keipert et al., 2014) . Collectively, these findings imply that in particular non-exercise conditions, such as mitochondrial dysfunction, FGF21 might act as a myokine.
Previous studies have shown FGF21 to be significantly increased in the systemic circulation in response to acute and long-term aerobic exercise (Cuevas-Ramos et al., 2012; Tanimura et al., 2016) . However, the present study showed no changes in arterialized FGF21 in response to maximal eccentric exercise. A possible explanation for these conflicting reports might be differences in the exercise modality and/or intensity used by those studies. Indeed, the present study used contractions involving one leg, which is less demanding on systemic stress than contractions using multiple limbs with a larger muscle mass involved. In the studies by Cuevas-Ramos et al. (2012) and Tanimura et al. (2016) , submaximal whole-body treadmill exercise was used at 75-85% of maximal oxygen consumption. This might suggest that in order to augment the release of FGF21 from the liver into the circulation, exercise involving substantial muscle mass might be required.
A novel aspect of the present study was the measurement of the bioactive form of FGF21 in response to exercise, whereas all studies to date involving exercise and FGF21 have measured only total FGF21. This is of clear importance, as it was recently shown that a large percentage of total FGF21 is not active (Umberger et al., 2014) .
Indeed, in the present study ∼65% of the total FGF21 was found to be in the bioactive form at baseline. Furthermore, maximal eccentric exercise did not increase the circulating bioactive form of FGF21, and there was no release from human skeletal muscle tissue into the systemic circulation. Interestingly, exercise significantly increased arterialized and venous FAP concentrations. The actions of FGF21 are attenuated by its proteolytic cleavage in plasma by FAP (Hager, Spahr, Xu, Salimi-Moosavi, & Hall, 2013) . FAP has an extensive tissue expression profile as a cell surface protease in addition to circulating in the blood of mice, non-human primates and humans (Zhen et al., 2016) .
In addition to FGF21, FAP has many other natural substrates, including neuropeptides, and although its activity has been shown to be increased in liver and plasma from patients with liver disease (Keane et al., 2013) , the impact of exercise on FAP activity, hence FGF21 biology, has remained largely unknown. In the present study, the In conclusion, the present study provides evidence that single-leg maximal eccentric contractions do not cause the release of either total or bioactive FGF21 from skeletal muscle into the systemic circulation in humans. In accordance, skeletal muscle FGF21 protein content did not increase in response to exercise, supporting the notion that FGF21 is neither induced nor released from skeletal muscle in response to maximal eccentric exercise. Finally, the data from this study showed a significant increase in circulating FAP levels during maximal eccentric contractions, with no apparent contribution to its release from the exercised leg. These findings raise the interesting possibility that the elevated levels of FAP might play a role in the inactivation of FGF21 during exercise. 
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